New standard regimen for ovarian cancer?
Clinicians need a good reason not to use it after the head-to-head trial, expert commentator says
Carboplatin-pegylated liposomal doxorubicin-bevacizumab should be a new standard regimen for women with recurrent platinum-sensitive ovarian cancer suitable for antiangiogenic treatment, say the authors of a clinical trial.
The non-blinded trial, dubbed AGO-OVAR2.21, which included Australian patients, compared outcomes in 345 women randomised to carboplatin-pegylated liposomal doxorubicin-bevacizumab (the experimental group) with those for 337 women who received the standard regimen of carboplatin-gemcitibine-bevacizumab (control).
